Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1992-1-15
|
pubmed:abstractText |
A total of 20 adults patients presenting with previously untreated lymphoblastic lymphoma underwent an intensive chemotherapy protocol. Either the BACOP or the m-BACOD regimen was used for induction. If the patients achieved a complete clinical remission (CR) after three courses, they were given intensive consolidation and maintenance chemotherapy based on a protocol that was modified from the L10/L17M regimen of the Memorial Sloan-Kettering group for acute lymphoblastic leukaemia and lymphoblastic lymphoma. Patients exhibiting localised areas of bulky disease were given additional involved-field radiotherapy. In all, 15 (75%) men and 5 (25%) women were entered in this study. Their median age was 28 years (mean, 30 years; range, 12-64 years). Overall, 3 (15%) had stage II disease, 3 (15%) had stage III disease and 14 (70%) had stage IV disease; 7 (35%) patients exhibited B symptoms and 4 (20%) had bulky disease. The overall (CR) rate was 10/20 (20%), and that following BACOP and m-BACOD therapy was 4/8 (50%) and 6/12 (50%), respectively. In all, 7 of the 10 complete responders (70%) relapsed. The disease-free survival of the ten who achieved a CR was 23% at 3 years. The overall survival of all 20 patients at 3 years was only 37%, and there were very few long-term survivors. More effective treatment for adult lymphoblastic lymphoma is required.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0344-5704
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
80-2
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1720710-Adult,
pubmed-meshheading:1720710-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1720710-Bleomycin,
pubmed-meshheading:1720710-Cyclophosphamide,
pubmed-meshheading:1720710-Dexamethasone,
pubmed-meshheading:1720710-Doxorubicin,
pubmed-meshheading:1720710-Female,
pubmed-meshheading:1720710-Humans,
pubmed-meshheading:1720710-Leucovorin,
pubmed-meshheading:1720710-Male,
pubmed-meshheading:1720710-Methotrexate,
pubmed-meshheading:1720710-Middle Aged,
pubmed-meshheading:1720710-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:1720710-Prednisone,
pubmed-meshheading:1720710-Remission Induction,
pubmed-meshheading:1720710-Vincristine
|
pubmed:year |
1991
|
pubmed:articleTitle |
Intensive chemotherapy for adult lymphoblastic lymphomas.
|
pubmed:affiliation |
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
|
pubmed:publicationType |
Journal Article
|